Talecris (Nasdaq: TLCR), the RTP-based blood plasma-based therapeutics firm, can expect to become part of Spain-based Grifols in coming based.

At a shareholders meeting in Spain on Tuesday, Grifols said in a statement that it expects final regulatory approval for the $4 billion deal in early June, according to Reuters.

Earlier this month, the Grifols-Talecris merger received tentative approval from the U.S. Federal Trade Commission. Both companies had to agree to make some adjustments in their holdings in order to address concerns about monopolization of the blood plasma business. (Read details here.

A Grifols-Talecris merger will produce the third largest blood plasma producer behind Baxter International and CSL.

Read the Reuters report here.

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.